scholarly journals Comparison between curative concurrent chemoradiotherapy followed by adjuvant chemotherapy and curative concurrent chemoradiotherapy alone in patients with locally advanced cervical carcinoma: a meta-analysis

2021 ◽  
Vol 42 (5) ◽  
pp. 1029
Medicine ◽  
2020 ◽  
Vol 99 (1) ◽  
pp. e18663
Author(s):  
Jiahao Zhu ◽  
Zheng Zhang ◽  
Dongyan Bian ◽  
Qingqing Chen ◽  
Qunchao Hu ◽  
...  

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16576-16576
Author(s):  
J. J. Zarba ◽  
F. R. Solórzano ◽  
P. Gonzalez Jasey ◽  
L. De Gregorio ◽  
R. Zelaya ◽  
...  

2019 ◽  
Vol 29 (1) ◽  
pp. 35-41
Author(s):  
Jiahao Zhu ◽  
Shengjun Ji ◽  
Qunchao Hu ◽  
Qingqing Chen ◽  
Zhengcao Liu ◽  
...  

BackgroundRecently, several studies observed that locally advanced cervical carcinoma with negative excision repair crross-complementation group one enzyme expression has better outcomes in cisplatin-based chemotherapy or chemoradiotherapy than carcinoma with positive excission repair cross-complementation group one enzyme expression. In this meta-analysis, we quantitatively evaluated the prognostic value of excission repair cross-complementation group one enzyme expression in locally advanced cervical carcinoma patients receiving platinum-based chemotherapy or chemoradiotherapy.MaterialsA systematic search for relevant studies was conducted in the PubMed, Cochrane Library, EMBASE and Medline databases. Fixed- or random-effects models were used for pooled analysis. The endpoints were overall survival and disease-free survival () reported as ORs and 95% CIs. The effects of excission repair cross-complementation group one enzyme expression on the clinicopathological parameters were measured by the pooled ORs and their 95% CIs.ResultsEight studies (612 patients in total) satisfied the inclusion criteria. Negative/low excission repair cross-complementation group one enzyme expression was significantly associated with better overall survival (OR, 1.92; 95% CI, 1.22 to 3.05; P = 0.005) and disease-free survival (OR, 5.77; 95% CI, 1.90 to 17.54; P = 0.002). Additionally, there were significant associations between excission repair cross-complementation group one enzyme expression and lymph node metastasis (OR, 2.57; 95% CI, 1.28 to 5.16; P = 0.008).ConclusionsThis meta-analysis suggested that pretreatment excission repair cross-complementation group one enzyme expression might be a useful biomarker to predict prognoses for locally advanced cervical carcinoma patients receiving platinum-based chemotherapy or chemoradiotherapy.


Sign in / Sign up

Export Citation Format

Share Document